Prothena Corporation PLC
NASDAQ:PRTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Prothena Corporation PLC
NASDAQ:PRTA
|
IE |
|
L
|
Lockheed Martin Corp
DUS:LOM
|
US |
|
C
|
Christiani & Nielsen Thai PCL
SET:CNT
|
TH |
|
Eureka Group Holdings Ltd
ASX:EGH
|
AU |
|
Hellenic Telecommunications Organization SA
F:OTES
|
GR |
|
M
|
Martifer SGPS SA
ELI:MAR
|
PT |
|
Relx PLC
LSE:REL
|
UK |
|
T
|
Tmp Group SpA
MIL:TMP
|
IT |
|
F
|
Firma Oponiarska Debica SA
WSE:DBC
|
PL |
|
Banco di Desio e della Brianza SpA
MIL:BDB
|
IT |
Intrinsic Value
Is PRTA undervalued or overvalued?
See the intrinsic value estimate for Prothena Corporation PLC and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
PRTA looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with PRTA’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Prothena Does
Prothena Corporation PLC is a biotechnology company that focuses on diseases caused by harmful proteins, especially neurodegenerative disorders and certain rare amyloid-related conditions. It does not sell a broad line of commercial medicines; instead, it develops drug candidates intended to stop or slow the protein misfolding and buildup that drives these illnesses.
- Headquarters
- Ireland IE
- Employees
- 67
- IPO date
- Dec 21, 2012
Revenue & Expenses Breakdown
Prothena Corporation PLC
Earnings Waterfall
Prothena Corporation PLC
The intrinsic value for Prothena Corporation PLC (PRTA) under the Base Case is hidden USD.
Compared with the current market price of 8.485 USD, the stock appears hidden.